Breast angiosarcoma is an exceptionally rare and aggressive cancer that develops in the blood or lymphatic vessels within breast tissue. Because this disease affects such a small number of people, medical teams worldwide continue to refine approaches to managing it and exploring new ways to improve outcomes for those diagnosed.

Understanding Treatment Goals and Current Challenges

When someone receives a diagnosis of breast angiosarcoma, the primary goal of treatment is to remove or destroy cancer cells completely and prevent the disease from spreading to other parts of the body. Given that angiosarcoma can be highly aggressive and tends to grow rapidly, swift action becomes essential. Treatment planning must consider multiple factors including the type of angiosarcoma, whether it appeared on its own or developed after prior breast cancer treatment, the size and location of the tumor, and the patient’s overall health status.

What makes breast angiosarcoma particularly challenging is that it doesn’t respond to treatments the same way common breast cancers do. Traditional breast cancer treatments like hormonal therapy—which blocks hormones that fuel certain cancers—typically don’t work for angiosarcoma because these tumors don’t depend on hormones to grow. Similarly, treatments that target specific proteins found in typical breast cancers often prove ineffective here. This means doctors must rely on a different set of tools, primarily surgery combined with chemotherapy, and sometimes radiation therapy.

Because breast angiosarcoma is so uncommon, representing only about 0.1% to 0.2% of all breast cancer cases, there are no large studies comparing different treatment approaches head-to-head. Medical societies and cancer centers draw recommendations from smaller case series, expert opinions, and experiences treating similar soft tissue cancers. Researchers continue investigating new therapies through clinical trials, searching for options that might work better than what’s currently available.

Standard Treatment Approaches for Breast Angiosarcoma

Surgery remains the cornerstone of treatment for breast angiosarcoma. For both primary angiosarcoma (which occurs without any known prior cause) and secondary angiosarcoma (which develops after radiation therapy or due to chronic swelling), the recommended approach is complete surgical removal of the tumor with wide margins. This means taking out the cancer along with a rim of healthy tissue around it to ensure no cancer cells are left behind. Because angiosarcoma can spread through breast tissue more extensively than it appears, achieving negative margins—meaning no cancer cells at the edges of removed tissue—is crucial but can be difficult.

For most patients with breast angiosarcoma, the surgical recommendation is mastectomy, which involves removing the entire breast. This more extensive surgery is typically chosen over breast-conserving surgery (lumpectomy) because angiosarcoma tends to involve multiple areas of the breast and has a high likelihood of coming back if any microscopic disease is left behind. In cases of secondary angiosarcoma that develops in the skin after radiation, surgery may need to remove not just the breast but also affected skin and sometimes underlying chest wall tissue.

The question of whether to use radiation therapy is complex in breast angiosarcoma. Since many secondary angiosarcomas actually develop because of previous radiation exposure, giving more radiation to an area already treated can be problematic. Some experts believe additional radiation might even encourage angiosarcoma cells to grow more aggressively. For primary angiosarcoma in patients who never received radiation before, some treatment centers do recommend radiation therapy after surgery, particularly if the tumor was large or margins were close. However, there’s no universal agreement on this approach, and decisions are made case by case.

Chemotherapy plays an important role in treating breast angiosarcoma, especially when tumors are large, high-grade (meaning cells look very abnormal under the microscope and are likely to grow quickly), or when there’s concern about spread to other organs. Unlike radiation, chemotherapy travels through the bloodstream and can reach cancer cells anywhere in the body. The most commonly used chemotherapy drugs for angiosarcoma are taxanes, particularly paclitaxel, which has shown meaningful activity against this cancer. Paclitaxel is typically given through an intravenous line once weekly over several months.

Another class of chemotherapy drugs frequently used is anthracyclines, with doxorubicin being the most common. Doxorubicin works by damaging the DNA inside cancer cells, preventing them from multiplying. It’s often combined with other chemotherapy drugs like dacarbazine in regimens known as AD, or with ifosfamide and mesna in regimens called AIM. These combination treatments may be more effective than single drugs but also cause more side effects.

Gemcitabine-based chemotherapy regimens represent another treatment option. Gemcitabine, which interferes with cancer cells’ ability to make new DNA, is often combined with docetaxel, vinorelbine, or dacarbazine. These combinations have demonstrated effectiveness in treating angiosarcoma and related soft tissue cancers. The choice among different chemotherapy regimens depends on factors like the patient’s age, other health conditions, previous treatments received, and how quickly treatment needs to start.

Chemotherapy can be given before surgery (called neoadjuvant chemotherapy) or after surgery (called adjuvant chemotherapy). When angiosarcomas are very large or located in positions that make complete surgical removal difficult, giving chemotherapy first may shrink the tumor and make surgery more successful. However, response rates to preoperative chemotherapy range from 40% to 50% even with the most active drug combinations, and the treatment causes significant side effects including fatigue, nausea, hair loss, increased infection risk, and potential long-term effects on the heart, especially with anthracyclines.

Treatment in Clinical Trials: Exploring New Approaches

Given that standard treatments for breast angiosarcoma produce less than ideal results, with many patients experiencing cancer recurrence even after aggressive therapy, researchers are actively investigating newer treatment strategies through clinical trials. These studies test promising medications and approaches that show potential in laboratory research or in treating other cancer types.

One area of active investigation involves targeted therapy drugs that attack specific molecular features of angiosarcoma cells. Since angiosarcomas arise from blood vessel lining cells, they often have abnormalities in pathways that control blood vessel growth. Scientists have discovered that many angiosarcomas have amplifications or mutations in genes related to vascular endothelial growth factor receptors (VEGFR), proteins that normally help form new blood vessels. Blocking these receptors might slow or stop angiosarcoma growth.

Pazopanib is a targeted drug that blocks multiple receptors involved in blood vessel formation, including VEGFR. In clinical studies examining pazopanib in patients with advanced angiosarcoma who had already received standard chemotherapy, some patients responded to treatment. In one retrospective study of 40 patients with angiosarcoma, eight showed tumor shrinkage with pazopanib treatment. The median time before cancer progressed was three months, and median overall survival reached 9.9 months. While these numbers might seem modest, they represent meaningful benefit for patients whose cancers had already grown through chemotherapy. Pazopanib is taken as a daily pill, making it more convenient than intravenous chemotherapy, though it can cause side effects including high blood pressure, diarrhea, liver problems, and fatigue.

Individual case reports have described exceptional responses to pazopanib in patients whose angiosarcomas harbored specific genetic alterations in vascular signaling genes. This suggests that testing tumors for these molecular features might help identify which patients are most likely to benefit from this targeted approach. Genetic testing of angiosarcoma tissue is becoming more common in specialized cancer centers and may guide treatment selection in the future.

Another targeted drug under investigation is sorafenib, which also blocks VEGFR and other kinases involved in cell growth and blood vessel formation. While sorafenib hasn’t been as extensively studied in angiosarcoma as pazopanib, it represents another option for patients whose cancers don’t respond to standard treatments or who cannot tolerate chemotherapy.

An intriguing and unconventional approach being studied involves repurposing propranolol, a widely used blood pressure medication from the beta-blocker family, to treat angiosarcoma. Propranolol blocks certain receptors that may promote blood vessel growth and tumor spread. In a small study from France, seven patients with advanced angiosarcoma received a combination of propranolol given twice daily along with weekly low-dose chemotherapy using vinblastine and methotrexate—an approach called metronomic chemotherapy where drugs are given more frequently at lower doses rather than at maximum tolerated doses with breaks in between.

The results from this propranolol combination were remarkable: all seven patients responded to treatment, with one achieving complete disappearance of detectable cancer and three showing very good partial responses. The median time before cancer progressed was eleven months, and median overall survival was sixteen months. Based on this and other promising data, propranolol received orphan drug status in Europe in 2017 for soft tissue sarcoma treatment. Subsequent research from the United States also showed that patients with metastatic angiosarcoma who took nonselective beta-blockers lived longer than those who didn’t. These findings have sparked interest in conducting larger clinical trials to confirm whether this readily available, inexpensive medication truly benefits angiosarcoma patients.

Immunotherapy, which harnesses the body’s immune system to fight cancer, represents another frontier in angiosarcoma research. Checkpoint inhibitors are immunotherapy drugs that release brakes on immune cells, allowing them to recognize and attack cancer cells. While these drugs have revolutionized treatment for some cancer types like melanoma and lung cancer, their role in angiosarcoma is still being defined through early-phase clinical trials. Initial results have been mixed, with some patients showing benefit while others don’t respond. Researchers are working to understand which angiosarcoma patients might be good candidates for immunotherapy.

Clinical trials testing these and other novel approaches are conducted primarily at major cancer centers in the United States, Europe, and other regions. Because breast angiosarcoma is so rare, these trials often enroll patients with any type of angiosarcoma or soft tissue sarcoma rather than focusing exclusively on breast cases. This makes enrollment challenging but increases the chance of gathering enough data to draw meaningful conclusions. Patients interested in clinical trial participation should discuss options with their oncology team, who can search trial databases and determine eligibility based on factors like cancer stage, prior treatments received, and other health conditions.

Most common treatment methods

• Surgery
  • Mastectomy is the recommended surgical approach, involving removal of the entire breast to ensure complete tumor removal with adequate margins
  • Surgery aims to achieve negative margins, meaning no cancer cells at the edges of removed tissue
  • In secondary angiosarcoma affecting the skin after radiation, surgery may include removal of affected skin and potentially underlying chest wall tissue
  • Complete surgical removal with wide margins remains the cornerstone of treatment for both primary and secondary breast angiosarcoma
• Chemotherapy with taxanes
  • Paclitaxel is the most commonly used taxane, typically administered intravenously once weekly
  • Taxanes have demonstrated meaningful activity specifically against angiosarcoma
  • This class of chemotherapy drugs is considered among the most effective for treating angiosarcoma
• Chemotherapy with anthracyclines
  • Doxorubicin is the primary anthracycline used, working by damaging DNA inside cancer cells
  • Often combined with other drugs in regimens like AD (doxorubicin plus dacarbazine) or AIM (doxorubicin plus ifosfamide and mesna)
  • Can cause significant side effects including increased infection risk, nausea, hair loss, and potential long-term heart damage
  • Alternative anthracyclines include epirubicin and liposomal doxorubicin
• Gemcitabine-based chemotherapy
  • Gemcitabine interferes with cancer cells’ ability to make new DNA
  • Commonly combined with docetaxel, vinorelbine, or dacarbazine
  • Represents an effective option for treating angiosarcoma and related soft tissue cancers
• Targeted therapy with kinase inhibitors
  • Pazopanib blocks multiple receptors involved in blood vessel formation including VEGFR
  • In studies of advanced angiosarcoma patients, pazopanib showed benefit with median progression-free survival of three months
  • Taken as a daily pill rather than intravenous infusion
  • Side effects include high blood pressure, diarrhea, liver problems, and fatigue
  • Sorafenib represents another VEGFR-blocking option under investigation
• Propranolol combined with metronomic chemotherapy
  • Propranolol is a beta-blocker normally used for blood pressure that may inhibit blood vessel growth
  • Given twice daily at 40 mg combined with weekly low-dose vinblastine and methotrexate
  • In a small study, all seven patients responded with median progression-free survival of eleven months
  • Granted orphan drug status in Europe for soft tissue sarcoma treatment
  • Research shows patients taking nonselective beta-blockers had increased survival
• Radiation therapy
  • Use is controversial and complex in breast angiosarcoma
  • Not recommended for secondary angiosarcoma that developed after previous radiation
  • May be considered after surgery for primary angiosarcoma in patients never previously irradiated, especially with large or high-grade tumors
  • Decisions are made on a case-by-case basis without universal agreement among experts
• Immunotherapy
  • Checkpoint inhibitors that release brakes on immune cells are being tested in clinical trials
  • Role in angiosarcoma treatment is still being defined through early-phase studies
  • Initial results have been mixed with some patients benefiting while others don’t respond